Sanofi India Q3 Results Review - Weak Performance, But Healthy Margins: ICICI Securities

Despite the high inflationary environment, we expect Ebitda margin to remain at ~26-27% over CY22E-CY23E.

ICICI Securities

04 Nov 2022, 01:50 PM IST

Sanofi India Ltd. (Source: Company's official FB page)

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Sanofi India Q3 Results Review - Weak Performance, But Healthy Margins: ICICI Securities

Despite the high inflationary environment, we expect Ebitda margin to remain at ~26-27% over CY22E-CY23E.

Choose a plan